face to face
various companies
under their brand
names such as
STPase by Cadila
Pharmaceuticals
and recombinant
streptokinase by
Shasun Drugs etc.
His team has also
developed a novel life-
saver thrombolytic
drug (Clot-specific
20
BioVoiceNews | September 2017
streptokinase), India’s
first bio-therapeutic
molecule.
The monoclonal
antibodies are highly
promising area.
Product like Rituximab
and Avastin have been
highly succesful in
treating cancer. Some
of them are already
being produced in
India. Only problem
which comes in
is that we need to
create resources
for the discovery of
new platforms. The
CSIR had actually
funded the major
product phage display
library. Due to it, the
monoclonal targets